Mark Roschewski M.D is a clinician scientist and currently serves as the Clinical Director of the Lymphoid Malignancies Branch (LYMB) of the Center for Cancer Research, National Cancer Institute (NCI) in Bethesda, MD. He began his career at Walter Reed Army Medical Center as an active-duty physician in the Army. After completing 12 years of active-duty Army service time, he transferred to the U.S. Public Health Service and joined the faculty at the NCI. Dr. Roschewski earned his B.A. degrees at University of Notre Dame and received his medical degree from the University of Nebraska Medical Center in Omaha, NE. He completed both internship and residency in internal medicine at Eisenhower Army Medical Center in Augusta, GA and hematology-oncology fellowship in medical oncology at the Walter Reed Army Medical Center in Washington, DC. The primary goal of his research team is to translate novel findings from the molecular biology of lymphoma into innovative therapies for lymphomas such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, EBV-associated lymphomas, and CNS lymphomas. Recent studies from the internationally acclaimed translational research team at NCI have demonstrated highly effective therapy for subtypes of DLBCL such as primary mediastinal B-cell lymphoma and Burkitt lymphoma. In addition, their group has demonstrated the effectiveness of targeted therapies including inhibitors of Bruton tyrosine kinase (Btk), ibrutinib and acalabrutinib. As a single agent, ibrutinib is effective in both primary and secondary CNS lymphomas; findings that have led to changes in treatment paradigms. In addition, his clinical team collaborates to develop circulating tumor DNA (ctDNA) as a predictive and prognostic biomarker in DLBCL and other lymphoma subtypes. He is the principal investigator on 8 active clinical trials and associate investigator on another 5 ongoing clinical trials at NCI. Dr. Roschewski is frequently invited to give presentations on his research to both national and international audiences, and he has published in high-impact scientific journals. He is often a reviewer for various scientific journals including Haematologica, Blood, Leukemia, New England Journal of Medicine, and Journal of Clinical Oncology in addition to his research activities, Dr. Roschewski is active in education and mentoring. He is an adjunct professor of medicine at the Uniformed Services University Health Sciences.